Radical surgical resection of advanced thymoma and thymic carcinoma infiltrating the heart or great vessels with cardiopulmonary bypass support

Table 1 Demographic and perioperative data

Pt	Age [years]/Sex/MG	Masaoka-Koga [3, 4]/WHO [5]	Induction therapy	Cannulation	Surgical approach: structures resected	CPB-/OP-time [min]	ICU-stay [days]
1	66/m/none	III/A	Octreotid/prednisone	Ascending aorta/femoral vein	Sternotomy: SCV, LBV, pericardium	94/269	28
2	27/m/none	IVa (left)/B3	PAC; octreotid/prednisone	Ascending aorta/RA	Sternotomy, left hemi clamshell thoracotomy: LBV, pericardium, left pleurectomy, left upper lobe	152/539	5
3	61/m/none	III/C	PAC	Femoral artery/femoral vein	Sternotomy: Chest wall, left upper lobe, pericardium, LBV, tumor debulking aortic arch and main pulmonary artery	378/664	28
4	35/f/MG	IVa (right)/B3	PAC; octreotid/prednisone	Ascending aorta/RA	Sternotomy, right hemi clamshell thoracotomy: EPP, pericardium, LBV	177/393	13
5	48/m/none	III/C	PAC	Ascending aorta/RA (hypothermic circulatory arrest)	Sternotomy: LBV, pericardium, aortic arch, brachiocephalic trunk, left carotid artery, left subclavian artery, wedge resections right and left lungs	240 (42)/467	26
6	41/m/MG	III/B2	None	Ascending aorta/RA	Sternotomy: LBV, ascending aorta	121/265	15

CPB cardiopulmonary bypass, EPP extrapleural pneumonectomy, f female, LBV left brachiocephalic vein, m male, MG myasthenia gravis, OP operation, PAC cisplatin, doxorubicin, cyclophosphamid, Pt patient, RA right atrium, SCV superior caval vein, WHO World Health Organication

ISSN: 1749-8090